Medial EarlySign

The new initiative will begin with a focus on gastric cancer. 

The collaboration will augment AI with remote care automation to improve patient care.

Medial Earlysign is helping hospitals turn data into action for particular high-need use cases, says CEO Ori Geva.

A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.